In addition to addressing the safety and efficacy of drug-eluting stents (DES) in general and relative to one another, randomized controlled trials and registries are now beginning to assess specific lesion subgroups for which DES are not currently approved in the US. These include in-stent restenosis, saphenous vein grafts, bifurcation lesions, left main disease, and acute myocardial infarction. Presenters at the “Enter the Drug-Eluting Stent Revolution V” summit, held in mid March immediately before the annual meeting of the American College of Cardiology, discussed existing data regarding the use of DES for these indications.
Proceedings of TCT 3, 9-11 (2006).
Fluent in Science 